Blood T cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapy

Abstract Background The tumor microenvironment is associated with prognosis in advanced non‐small cell lung carcinoma (NSCLC). The aim of this study was to explore the relationship between blood T cell diversity and survival of patients treated with pemetrexed‐based chemotherapy for nonsquamous NSCL...

Full description

Bibliographic Details
Main Authors: Li Qian, Zhang Zhaohui, Xu Yaping, Liu Zhentian, Liu Zhentao, Wang Qiqi, Gu Yangchun, Liu Yan'e, Yin Wencheng, Yi Fumei, Yao Yanhong, Cao Baoshan, Liang Li
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Thoracic Cancer
Subjects:
Online Access:https://doi.org/10.1111/1759-7714.13771
id doaj-3c6485b0183e418680c2fa381e51666b
record_format Article
spelling doaj-3c6485b0183e418680c2fa381e51666b2021-04-02T04:50:28ZengWileyThoracic Cancer1759-77061759-77142021-04-01127997100510.1111/1759-7714.13771Blood T cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapyLi Qian0Zhang Zhaohui1Xu Yaping2Liu Zhentian3Liu Zhentao4Wang Qiqi5Gu Yangchun6Liu Yan'e7Yin Wencheng8Yi Fumei9Yao Yanhong10Cao Baoshan11Liang Li12Department of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaDepartment of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaDepartment of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaDepartment of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaDepartment of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaDepartment of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaDepartment of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaDepartment of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaDepartment of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaDepartment of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaDepartment of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaDepartment of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaDepartment of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing ChinaAbstract Background The tumor microenvironment is associated with prognosis in advanced non‐small cell lung carcinoma (NSCLC). The aim of this study was to explore the relationship between blood T cell diversity and survival of patients treated with pemetrexed‐based chemotherapy for nonsquamous NSCLC. Methods This prospective clinical study enrolled 26 patients with advanced NSCLC treated with 4–6 cycles of first‐line pemetrexed combined with platinum‐based therapy. The complementarity‐determining region 3 (CDR3) located in the T cell receptor beta chain (TCR β chain) was captured and deeply sequenced using next‐generation sequencing (NGS) technology, and the correlation between TCR changes and efficacy after chemotherapy was analyzed. Results Patients with an inferior quarter diversity index showed a significantly shorter progression‐free survival (PFS) than the others (median, 5.0 months vs. 8.1 months, P = 0.014). After two cycles of chemotherapy, the TCR diversity was significantly higher than the baseline (P = 0.034). Just as with the baseline, patients with an inferior quarter diversity index at the endpoint of cycle 2 showed a shorter progression‐free survival (PFS) than the others (median, 5.0 months vs. 8.4 months, P = 0.024). Conclusions In advanced NSCLC patients treated with first‐line pemetrexed combined with platinum, the low level of blood TCR diversity at baseline with an endpoint of two cycles of chemotherapy was correlated with a poor prognosis.https://doi.org/10.1111/1759-7714.13771Advanced non‐small cell lung carcinomaT cell diversitytumor microenvironment
collection DOAJ
language English
format Article
sources DOAJ
author Li Qian
Zhang Zhaohui
Xu Yaping
Liu Zhentian
Liu Zhentao
Wang Qiqi
Gu Yangchun
Liu Yan'e
Yin Wencheng
Yi Fumei
Yao Yanhong
Cao Baoshan
Liang Li
spellingShingle Li Qian
Zhang Zhaohui
Xu Yaping
Liu Zhentian
Liu Zhentao
Wang Qiqi
Gu Yangchun
Liu Yan'e
Yin Wencheng
Yi Fumei
Yao Yanhong
Cao Baoshan
Liang Li
Blood T cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapy
Thoracic Cancer
Advanced non‐small cell lung carcinoma
T cell diversity
tumor microenvironment
author_facet Li Qian
Zhang Zhaohui
Xu Yaping
Liu Zhentian
Liu Zhentao
Wang Qiqi
Gu Yangchun
Liu Yan'e
Yin Wencheng
Yi Fumei
Yao Yanhong
Cao Baoshan
Liang Li
author_sort Li Qian
title Blood T cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapy
title_short Blood T cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapy
title_full Blood T cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapy
title_fullStr Blood T cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapy
title_full_unstemmed Blood T cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapy
title_sort blood t cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapy
publisher Wiley
series Thoracic Cancer
issn 1759-7706
1759-7714
publishDate 2021-04-01
description Abstract Background The tumor microenvironment is associated with prognosis in advanced non‐small cell lung carcinoma (NSCLC). The aim of this study was to explore the relationship between blood T cell diversity and survival of patients treated with pemetrexed‐based chemotherapy for nonsquamous NSCLC. Methods This prospective clinical study enrolled 26 patients with advanced NSCLC treated with 4–6 cycles of first‐line pemetrexed combined with platinum‐based therapy. The complementarity‐determining region 3 (CDR3) located in the T cell receptor beta chain (TCR β chain) was captured and deeply sequenced using next‐generation sequencing (NGS) technology, and the correlation between TCR changes and efficacy after chemotherapy was analyzed. Results Patients with an inferior quarter diversity index showed a significantly shorter progression‐free survival (PFS) than the others (median, 5.0 months vs. 8.1 months, P = 0.014). After two cycles of chemotherapy, the TCR diversity was significantly higher than the baseline (P = 0.034). Just as with the baseline, patients with an inferior quarter diversity index at the endpoint of cycle 2 showed a shorter progression‐free survival (PFS) than the others (median, 5.0 months vs. 8.4 months, P = 0.024). Conclusions In advanced NSCLC patients treated with first‐line pemetrexed combined with platinum, the low level of blood TCR diversity at baseline with an endpoint of two cycles of chemotherapy was correlated with a poor prognosis.
topic Advanced non‐small cell lung carcinoma
T cell diversity
tumor microenvironment
url https://doi.org/10.1111/1759-7714.13771
work_keys_str_mv AT liqian bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy
AT zhangzhaohui bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy
AT xuyaping bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy
AT liuzhentian bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy
AT liuzhentao bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy
AT wangqiqi bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy
AT guyangchun bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy
AT liuyane bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy
AT yinwencheng bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy
AT yifumei bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy
AT yaoyanhong bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy
AT caobaoshan bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy
AT liangli bloodtcelldiversityassociatedwiththeprognosisofadvancednonsmallcelllungcarcinomatreatedwithfirstlinepemetrexedbasedchemotherapy
_version_ 1724172920317542400